Amanda Garrido holds a PhD in pharmacy (2019) and a PhD in organic chemistry (2020) from the University of Tours. During her thesis in medicinal chemistry, she worked on the design of new heterocyclic compounds with antitumor properties against breast cancer. After conducting an post-doctoral position at Centre d’études et de recherche sur le médicament de Normandie (CERMN) on the synthesis of new radiotracers for medical imaging, she was recruited as a lecturer at the Institute of Pharmaceutical and Biological Sciences at Claude Bernard Lyon 1 University (2021). She teaches organic chemistry to pharmacy students and carries out research in the design of new antibiotics in the fight against antibiotic resistance.
Medicinal chemistry ; antibiotic resistance ; heterocyclic chemistry
- Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry : an extensive review.
Garrido, A.; Vera, G.; Delaye, P.O.; Enguehard-Gueiffier, C. Eur. J. Med. Chem. 2021, 226, 113867.
- hERG toxicity assessment: guidelines for drug design.
Garrido, A.; Lepailleur, A.; Mignani, S. M.; Dallemagne, P.; Rochais, C. Eur. J. Med. Chem. 2020, 195, 112290.
- Direct access to highly functionalised benzimidazoles and benzoxazoles from a common precursor.
Garrido, A.; Delaye, P.O.; Quintin, F.; Lameiras, P.; Gueiffier, A.; Thibonnet, J.; Petrignet, J. Synthesis 2019, 51, 4006-4013.